These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 27251573)

  • 21. A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma.
    Duray E; Lejeune M; Baron F; Beguin Y; Devoogdt N; Krasniqi A; Lauwers Y; Zhao YJ; D'Huyvetter M; Dumoulin M; Caers J
    J Hematol Oncol; 2021 Nov; 14(1):183. PubMed ID: 34727950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
    Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
    Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting NAD
    Kennedy BE; Sadek M; Elnenaei MO; Reiman A; Gujar SA
    Trends Cancer; 2020 Jan; 6(1):9-12. PubMed ID: 31952784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments.
    Geis M; Nowotny B; Bohn MD; Kouhestani D; Einsele H; Bumm T; Stuhler G
    Commun Biol; 2021 Jan; 4(1):44. PubMed ID: 33420283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38.
    Bolzoni M; Toscani D; Costa F; Vicario E; Aversa F; Giuliani N
    Immunol Lett; 2019 Jan; 205():65-70. PubMed ID: 29702149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD38 as a therapeutic target.
    Stevenson GT
    Mol Med; 2006; 12(11-12):345-6. PubMed ID: 17380203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
    de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
    J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD38 antibodies in multiple myeloma: back to the future.
    van de Donk NWCJ; Richardson PG; Malavasi F
    Blood; 2018 Jan; 131(1):13-29. PubMed ID: 29118010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers.
    Jiao Y; Yi M; Xu L; Chu Q; Yan Y; Luo S; Wu K
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1295-1308. PubMed ID: 32822558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach.
    Alici E; Chrobok M; Lund J; Ahmadi T; Khan I; Duru AD; Nahi H
    Br J Haematol; 2016 Aug; 174(3):473-7. PubMed ID: 26455823
    [No Abstract]   [Full Text] [Related]  

  • 31. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma.
    Ellis JH; Barber KA; Tutt A; Hale C; Lewis AP; Glennie MJ; Stevenson GT; Crowe JS
    J Immunol; 1995 Jul; 155(2):925-37. PubMed ID: 7608568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity.
    Yu T; Qiao C; Lv M; Tang L
    BMC Biotechnol; 2019 May; 19(1):28. PubMed ID: 31118070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
    Frerichs KA; Nagy NA; Lindenbergh PL; Bosman P; Marin Soto J; Broekmans M; Groen RWJ; Themeli M; Nieuwenhuis L; Stege C; Nijhof IS; Mutis T; Zweegman S; Lokhorst HM; van de Donk NWCJ
    Expert Rev Clin Immunol; 2018 Mar; 14(3):197-206. PubMed ID: 29465271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.
    Feng X; Zhang L; Acharya C; An G; Wen K; Qiu L; Munshi NC; Tai YT; Anderson KC
    Clin Cancer Res; 2017 Aug; 23(15):4290-4300. PubMed ID: 28249894
    [No Abstract]   [Full Text] [Related]  

  • 35. The Circular Life of Human CD38: From Basic Science to Clinics and Back.
    Horenstein AL; Faini AC; Morandi F; Bracci C; Lanza F; Giuliani N; Paulus A; Malavasi F
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33096610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanobodies targeting norovirus capsid reveal functional epitopes and potential mechanisms of neutralization.
    Koromyslova AD; Hansman GS
    PLoS Pathog; 2017 Nov; 13(11):e1006636. PubMed ID: 29095961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro affinity maturation to improve the efficacy of a hypoxia-inducible factor 1α single-domain intrabody.
    Hu M; Kang G; Cheng X; Wang J; Li R; Bai Z; Yang D; Huang H
    Biochem Biophys Res Commun; 2020 Sep; 529(4):936-942. PubMed ID: 32819602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma.
    Rabut É; Castro-Fernandez A; Le Gall V; Meknache N
    Ann Biol Clin (Paris); 2017 Jun; 75(3):351-355. PubMed ID: 28540859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human CD38 regulates B cell antigen receptor dynamic organization in normal and malignant B cells.
    Camponeschi A; Kläsener K; Sundell T; Lundqvist C; Manna PT; Ayoubzadeh N; Sundqvist M; Thorarinsdottir K; Gatto M; Visentini M; Önnheim K; Aranburu A; Forsman H; Ekwall O; Fogelstrand L; Gjertsson I; Reth M; Mårtensson IL
    J Exp Med; 2022 Sep; 219(9):. PubMed ID: 35819358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational Design and Identification of Small-Molecule Allosteric Inhibitors of CD38.
    Yang L; Li T; Li S; Wu Y; Shi X; Jin H; Liu Z; Zhao Y; Zhang L; Lee HC; Zhang L
    Chembiochem; 2019 Oct; 20(19):2485-2493. PubMed ID: 31081167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.